<![CDATA[Navigating Second-Line CAR-T Candidacy and Sequencing in DLBCL]]>

Summary

A multidisciplinary panel discussed CAR-T candidacy and sequencing strategies for second-line treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. This is a routine clinical discussion without new trial data, regulatory decisions, or company-specific announcements.